SNDX-5613

SNDX-5613 is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥2175.00

1740.00

- +
10mg

￥3775.00

3020.00

- +
25mg

￥7550.00

6040.00

- +
50mg

￥11875.00

9500.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

SNDX-5613 has anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8). SNDX-5613 doesn't inhibit growth of HL-60, a promyelocytic leukemia cell line lacking an MLL rearrangement , indicating selective activity towards leukemic cells lines that harbor MLL-rearranged (MLLr) fusion proteins.^[1]

SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 xenografts nude rats.^[1]

[1] SNDX-5613 Briefing Document for the 18 June 2020 Oncologic Drugs Advisory Committee Pediatric Subcommittee